ReviewEmerging infectious diseases2023
Crimean-Congo Hemorrhagic Fever, Spain, 2013-2021.
Review in Emerging infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Meta-analysis of Maternal and Fetal Outcomes of Crimean-Congo Hemorrhagic Fever during Pregnancy.Emerging infectious diseases · 2026Pooled it
- Dual-antigen AdV5 vaccines against Crimean-Congo hemorrhagic fever virus induce superior humoral and Th1-biased cellular immunity.Scientific reports · 2026Article
- Diagnosis, management, and prevention of Crimean-Congo haemorrhagic fever: a Delphi-based consensus study in Türkiye.EClinicalMedicine · 2026Article
- Crimean-Congo hemorrhagic fever virus Africa 1 lineage inJournal of virology · 2026Article
- Apiol-Rich and Caryophyllene-Oxygenated Essential Oils from AmazonianMolecules (Basel, Switzerland) · 2026Article
- Crimean-Congo Hemorrhagic Fever in Children: Secondary Hemophagocytic Lymphohistiocytosis and Time-course of Biomarkers in a Single-Center Cohort (2019-25).Journal of tropical pediatrics · 2026Article
- Crimean-Congo hemorrhagic fever: An emerging threat in Europe.Virologica Sinica · 2026Review
- Clinical Characteristics, Risk Factors, and Predictors of Fatal Outcomes and Prolonged Hospitalization of Crimean-Congo Hemorrhagic Fever Cases in Basrah, Iraq.Infectious disease reports · 2026Article
- Human antibody targeting Crimean-Congo hemorrhagic fever virus glycoprotein 38 protects mice against heterologous virus challenge.The Journal of clinical investigation · 2026Article
- Host Community Traits Driving Crimean-Congo Hemorrhagic Fever Virus Maintenance in Iberian Ecosystems.Transboundary and emerging diseases · 2026Article
- Detection and genetic characterization of Crimean-Congo hemorrhagic fever virus in ticks from western Spain (2017, 2020-2024).Frontiers in veterinary science · 2026Article
- Tracking invasion events: phylogeography of Hyalomma marginatum in the Mediterranean basin with a focus on Southern France.Parasites & vectors · 2025Article
- Molecular and Clinical Characterization of Crimean-Congo Hemorrhagic Fever in Bulgaria, 2015-2024.Pathogens (Basel, Switzerland) · 2025Article
- Review
- Evidence of Crimean-Congo hemorrhagic fever virus in livestock and wildlife in Northeastern Portugal.Scientific reports · 2025Article
- Impact of Human Granulocytic Anaplasmosis in Spain from 1997 to 2022.Tropical medicine and infectious disease · 2025Review
- Serological evaluation of Crimean-Congo Hemorrhagic fever in humans with High-Risk professional exposure and in residual sera collected in 2022-2023 across Corsica (France).One health (Amsterdam, Netherlands) · 2025Article
- Article
- Cases of high-consequence infectious diseases identified in the UK, 1962-2023.Journal of medical microbiology · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crimean-Congo hemorrhagic fever (CCHF) is a viral infectious disease for which distribution of the main vector, Hyalomma spp. ticks, is expanding. We analyzed all 10 cases of CCHF diagnosed in Spain during 2013-2021; case-patient median age was 56.5 years, and 7 were men. We identified CCHF virus genotypes III and V. Six case-patients acquired the infection in urban areas. Sixty percent of patients were infected in summer and 40% in spring. Two patients met criteria for hemophagocytic syndrome. Seven patients survived. The epidemiologic pattern of CCHF in Spain is based on occasional cases with an elevated mortality rate. Genotype III and, to a less extent also genotype V, CCHF circulates in humans in a common geographic area in Spain. Those data suggest that the expansion pathways are complex and may change over time. Physicians should remain alert to the possibility of new CCHF cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.